MDxHealth (MDXH) EBIT (2021 - 2026)

MDxHealth (MDXH) has 6 years of EBIT data on file, last reported at -$7.3 million in Q1 2026.

• Quarterly EBIT fell 59.18% year-over-year to -$7.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$17.1 million (up 24.59% YoY) and the FY2025 annual result came in at -$14.4 million, up 41.72% from the prior year.
• EBIT eased to -$7.3 million in Q1 2026 per MDXH's latest filing, from -$5.3 million in the prior quarter.
• The five-year high for EBIT was $7.8 million in Q2 2022, with the low at -$17.7 million in Q2 2023.
• Average EBIT over 5 years is -$6.2 million, with a median of -$6.3 million recorded in 2023.
• Year-over-year, EBIT tumbled 326.33% in 2023 and soared 74.17% in 2025.
• MDxHealth's EBIT stood at -$8.9 million in 2022, then grew by 29.52% to -$6.3 million in 2023, then gained by 26.93% to -$4.6 million in 2024, then dropped by 14.19% to -$5.3 million in 2025, then sank by 38.79% to -$7.3 million in 2026.
• Business Quant data shows MDXH's EBIT at -$7.3 million in Q1 2026, -$5.3 million in Q4 2025, and -$2.6 million in Q3 2025.